Fasudil
As of the edition of 20 October 2026, Fasudil is a small molecule: stopped in 2011; acts on ROCK1 and ROCK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2011
- Kind
- Small molecule
- Registered trials
- 15, 1 stopped early
- Disease areas
- Nervous system; Heart and blood vessels; Cancer; Nutrition and metabolism; Mental health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 12 | 5 | 4 | 1 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 15 |